Nuwellis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 09, 2022 at 08:06 am EDT
Share
Nuwellis, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 2.21 million compared to USD 2.51 million a year ago. Net loss was USD 4.29 million compared to USD 4.73 million a year ago. Basic loss per share from continuing operations was USD 41 compared to USD 72 a year ago.
For the six months, sales was USD 4.14 million compared to USD 4.43 million a year ago. Net loss was USD 8.76 million compared to USD 9.95 million a year ago. Basic loss per share from continuing operations was USD 83 compared to USD 204 a year ago.
Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
NUWELLIS, INC. 
